drugset / Trial / NCT00002009

A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia

NCT00002009 ↗

Phase 1 Completed Sandoz
Treatment

Summary

To determine the maximum tolerated dose (MTD) and toxicity of sargramostim (recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF) given by continuous intravenous infusion (CIV) in patients with leukopenia in association with AIDS virus infection. In addition, single dose and steady state pharmacokinetics will also be determined.

Timeline

Start
—
Primary completion
—
Completion
—

Publications

  • Background Barbarini G, Garavelli G, Grisorio B, Barbaro G, Giangregorio F. GM-CSF in HIV related leukopenia: efficacy and tolerability of three months therapy on 50 patients. Int Conf AIDS. 1996 Jul 7-12;11(1):313 (abstract no TuB2279)

Drugs

EvaluationDrugModalityDoseRoute
Subject sargramostim Protein / enzyme biologic — Intravenous